hucMet27Gv1.3Hinge-L-DM21

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamehucMet27Gv1.3Hinge-L-DM21

Drug Alias NameADC targeting MET-amplification with a peptide-linked maytansinoid (ImmunoGen)maytansinoid based antibody-drug conjugate (ImmunoGen)anti-cMet antibody drug conjugate (ImmunoGen)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionHepatocyte growth factor receptor inhibitors

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A